Drug Trial Radar · NCT07519330
Clinical Study to Evaluate the Efficacy and Safety of HH-006 in Patients With Chronic Hepatitis B Virus Infection
Last checked: Nov 19, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
May 14, 2026
Primary completion
Feb 28, 2028
Study completion Mar 22, 2028
Sponsor
- Lead sponsor
- Huahui HealthIndustry
- Sponsor type
- Industry
- First posted
- Apr 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study HH006-202 is designed to assesses the efficacy and safety of HH-006 in adults chronic HBV infection. Eligible participants will receive study treatment for 48 weeks. All treated patients will also undergo a follow-up period after last study drug treatment.
Conditions
- Chronic Hepatitis B Virus Infection
Interventions
HH-006Biological
HH-006 480 mg SC injection every one week for 4 weeks and followed by 240 mg QW for 44 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- HBsAg change from baselineTime frame: week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chongqing University Three Gorges Hospital
Chongqing, Chongqing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.